Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Meta Platforms Inc (META) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Meta Platforms Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Meta Platforms Inc trades at $599.15 (market cap $1.52T). The key difference: Meta Platforms Inc is far larger — about 161.9× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Meta Platforms Inc pays a 0.35% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | META | |
|---|---|---|
Market Cap | $9.39B | $1.52T |
Sector | Health | Media |
52-Week High | $356.25 | $790.00 |
52-Week Low | $241.71 | $525.72 |
Enterprise Value | $9.14B | $1.54T |
Volume | — | 24,093,972 |
Dividend Yield | — | 0.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
META stock trades at $594.92, up 0.48% over 24 hours, with a bearish technical signal driven by moving averages and overbought short-term RSI. The company reported strong Q1 2026 earnings of $10.44 EPS, beating expectations, but missed in Q2 2026. Revenue growth remains robust, with 2025 revenue at $200.97 billion, though net income dipped to $60.46 billion. Recent news highlights the launch of AI model Muse Spark and a legal ruling in Massachusetts over youth addiction claims.
Outlook is mixed: analyst consensus is bullish with a $761.95 price target, citing AI innovations and solid fundamentals, but risks include high capital expenditure, regulatory lawsuits, and competitive pressures. The stock's valuation metrics like P/E of 22.41 suggest room for growth if execution continues, but investors should weigh legal and market volatility concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
